Haemonetics [HAE] vs Masimo [MASI] Detailed Stock Comparison

Haemonetics Corporation

NYSE
Loading...

Masimo Corporation

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Haemonetics Corporation wins in 11 metrics, Masimo Corporation wins in 9 metrics, with 0 ties. Haemonetics Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Haemonetics Corporation Masimo Corporation Better
P/E Ratio (TTM) 16.42 46.47 Haemonetics Corporation
Price-to-Book Ratio 3.06 12.89 Haemonetics Corporation
Debt-to-Equity Ratio 134.40 77.55 Masimo Corporation
PEG Ratio 0.60 27.03 Haemonetics Corporation
EV/EBITDA 9.95 28.15 Haemonetics Corporation
Profit Margin (TTM) 13.31% -9.92% Haemonetics Corporation
Operating Margin (TTM) 21.01% 18.52% Haemonetics Corporation
EBITDA Margin (TTM) 21.01% 18.52% Haemonetics Corporation
Return on Equity 19.30% 23.43% Masimo Corporation
Return on Assets (TTM) 6.45% 8.86% Masimo Corporation
Free Cash Flow (TTM) $142.45M $193.10M Masimo Corporation
1-Year Return 0.15% 9.82% Masimo Corporation
Price-to-Sales Ratio (TTM) 2.10 6.12 Haemonetics Corporation
Enterprise Value $3.63B $9.72B Masimo Corporation
EV/Revenue Ratio 2.76 6.37 Haemonetics Corporation
Gross Profit Margin (TTM) 59.71% 59.95% Masimo Corporation
Revenue per Share (TTM) $28 $28 Masimo Corporation
Earnings per Share (Diluted) $3.63 $3.84 Masimo Corporation
Beta (Stock Volatility) 0.36 1.20 Haemonetics Corporation
Short % of Float 6.00% 6.81% Haemonetics Corporation

Haemonetics Corporation vs Masimo Corporation Stock Performance Analysis

Loading Price Chart...

HAE
MASI

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Haemonetics Corporation-0.74%-1.91%19.09%0.38%-19.57%-17.63%
Masimo Corporation0.03%0.00%0.32%1.95%29.47%40.33%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Haemonetics Corporation0.15%-23.06%23.11%138.01%105.17%166.65%
Masimo Corporation9.82%9.28%-15.51%257.33%509.04%791.36%

Performance & Financial Health Analysis: Haemonetics Corporation vs Masimo Corporation

MetricHAEMASI
Market Information
Market Cap i$2.77B$9.36B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i672,226558,463
90 Day Avg. Volume i726,3091,362,548
Last Close$65.88$178.78
52 Week Range$47.32 - $87.32$125.94 - $179.00
% from 52W High-24.55%-0.12%
All-Time High$142.11 (Feb 08, 2021)$305.21 (Nov 15, 2021)
% from All-Time High-53.64%-41.42%
Growth Metrics
Quarterly Revenue Growth-0.03%0.12%
Quarterly Earnings Growth0.19%N/A
Financial Health
Profit Margin (TTM) i0.13%-0.10%
Operating Margin (TTM) i0.21%0.19%
Return on Equity (TTM) i0.19%0.23%
Debt to Equity (MRQ) i134.4077.55
Cash & Liquidity
Book Value per Share (MRQ)$19.46$13.84
Cash per Share (MRQ)$7.82$2.92
Operating Cash Flow (TTM) i$338.84M$217.80M
Levered Free Cash Flow (TTM) i$335.05M$316.41M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/A$0.00

Valuation & Enterprise Metrics Analysis: Haemonetics Corporation vs Masimo Corporation

MetricHAE (Apr 24, 2026)MASI (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i16.4246.47
Forward P/E i11.2727.03
PEG Ratio i0.6027.03
Price to Sales (TTM) i2.106.12
Price to Book (MRQ) i3.0612.89
Market Capitalization
Market Capitalization i$2.77B$9.36B
Enterprise Value i$3.63B$9.72B
Enterprise Value Metrics
Enterprise to Revenue i2.766.37
Enterprise to EBITDA i9.9528.15
Risk & Other Metrics
Beta i0.361.20
Book Value per Share (MRQ) i$19.46$13.84

Financial Statements Comparison: Haemonetics Corporation vs Masimo Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricHAE (2025)MASI (2025)
Revenue/Sales i1.36B1.53B
Cost of Goods Sold i611.87M581.70M
COGS % of Revenue i45.0%38.1%
Gross Profit i748.96M945.20M
Gross Margin i55.0%61.9%
Research & Development i62.72M126.40M
Operating Income (EBIT) i201.19M312.80M
Operating Margin i14.8%20.5%
EBITDA i316.77M355.00M
EBITDA Margin i23.3%23.2%
Pre-Tax Income i212.07M272.60M
Pre-Tax Income % of Revenue i15.6%17.9%
Income Tax i44.39M64.90M
Income Tax % of Revenue i3.3%4.3%
Net Income (Profit) i167.68M-151.50M
Profit Margin i12.3%-9.9%

Balance Sheet & Liquidity Metrics

MetricHAE (2025)MASI (2025)
Cash & Equivalents i306.76M152.30M
Total Current Assets i934.98M926.00M
Total Current Assets % of Revenue i68.7%60.6%
Total Current Liabilities i578.11M371.60M
Total Current Liabilities % of Revenue i42.5%24.3%
Long-Term Debt i921.23M544.90M
Long-Term Debt % of Revenue i67.7%35.7%
Total Shareholders Equity i820.84M721.20M
Retained Earnings i352.17M1.34B
Retained Earnings % of Revenue i25.9%87.7%
Property, Plant & Equipment i395.15M237.20M

Cash Flow Statement Comparison

MetricHAE (2025)MASI (2025)
Operating Cash Flow i214.01M198.40M
Operating Cash Flow % of Revenue i15.7%13.0%
Capital Expenditures i23.25M200,000
Free Cash Flow i142.45M193.10M
FCF Margin i10.5%12.6%
Debt Repayment i-502.69M-1.28B
Common Stock Repurchase i-225.00M-363.70M

Short Interest & Institutional Ownership Analysis

MetricHAEMASI
Shares Short i2.07M3.25M
Short Ratio i2.591.68
Short % of Float i6.00%6.81%
Shares Outstanding i46.83M52.10M
Float Shares i45.93M47.45M
% Held by Insiders i1.19%5.00%
% Held by Institutions i115.88%109.04%
% Held by Public i-17.07%-14.04%

Dividend Analysis & Yield Comparison: Haemonetics Corporation vs Masimo Corporation

MetricHAEMASI
Last 12-Month Dividend iN/A$0.00
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/A$0.00
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/A$0.00
Ex-Dividend DateN/AN/A